In its software, Lykos describes MDMA as a catalyst for the therapeutic course of action, And that's why it received much focus. That isn't predicted to become just as much of a hold-up for other psychedelics, though. “The remainder of us are learning molecules that do not demand a similar diploma of therapy,” claims Kabir Nath, CEO of Compass